Filing Flows › Maxcyte (MXCT) › How it makes money
How Maxcyte (MXCT) makes money
Maxcyte (MXCT) made $7.3M of revenue in the second quarter 2026 (Q2 2026), -15% from a year earlier. Product sales brought in $4.1M (56%); Licenses brought in $2.6M (36%); Assay and other service revenue brought in $583K (8%).
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Product sales | $4.1M | 56.4% | +13% | -22% |
| Licenses | $2.6M | 35.6% | -53% | -12% |
| Assay and other service revenue | $583K | 8.0% | +21% | +88% |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $7.3M | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $7.3M | -14% |
| Q1 2026 | $9.7M | -7% |
| Q4 2025 | $7.3M | -16% |
| Q3 2025 | $6.8M | -16% |
| Q2 2025 | $8.5M | -18% |
| Q1 2025 | $10.4M | -8% |
| Q4 2024 | $8.7M | -44% |
From Maxcyte's 10-Q filed Aug 13, 2026 (on EDGAR).
Questions
How does Maxcyte make money?
Maxcyte (MXCT) made $7.3M of revenue in the second quarter 2026 (Q2 2026), -15% from a year earlier. Product sales brought in $4.1M (56%); Licenses brought in $2.6M (36%); Assay and other service revenue brought in $583K (8%).
What is Maxcyte's biggest business?
Product sales: $4.1M in the second quarter 2026, 56% of revenue, -22% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.